Search research articles
Contact Us
Filters
Showing results (171-180 of 178) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 178 results.
Cancer Medicine
|
November 8, 2022
Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers
Tomoharu Mori, Yusuke Okamoto, Anfeng Mu, et al.
Breast Cancer (Tokyo, Japan)
|
March 17, 2023
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients
Masayuki Nagahashi, YiWei Ling, Chie Toshikawa, et al.
JCO Precision Oncology
|
June 13, 2020
Actionable gene alterations in an Asian population with triple-negative breast cancer
Masayuki Nagahashi, YiWei Ling, Tetsu Hayashida, et al.
Cancer Research
|
March 18, 2004
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
Yurika Sugita, Hisashi Wada, Shoichiro Fujita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2025
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy
Hope S Rugo, David W Cescon, Mark E Robson, et al.
International Journal of Clinical Oncology
|
September 29, 2015
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes
Chiyomi Egawa, Kouichi Hirokaga, Shintaro Takao, et al.
Breast Cancer (Tokyo, Japan)
|
October 13, 2016
Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes
Kaori Tane, Chiyomi Egawa, Shintaro Takao, et al.
Lancet (London, England)
|
April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 178) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 178 results.
Cancer Medicine
|
November 8, 2022
Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers
Tomoharu Mori, Yusuke Okamoto, Anfeng Mu, et al.
Breast Cancer (Tokyo, Japan)
|
March 17, 2023
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients
Masayuki Nagahashi, YiWei Ling, Chie Toshikawa, et al.
JCO Precision Oncology
|
June 13, 2020
Actionable gene alterations in an Asian population with triple-negative breast cancer
Masayuki Nagahashi, YiWei Ling, Tetsu Hayashida, et al.
Cancer Research
|
March 18, 2004
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
Yurika Sugita, Hisashi Wada, Shoichiro Fujita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2025
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy
Hope S Rugo, David W Cescon, Mark E Robson, et al.
International Journal of Clinical Oncology
|
September 29, 2015
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes
Chiyomi Egawa, Kouichi Hirokaga, Shintaro Takao, et al.
Breast Cancer (Tokyo, Japan)
|
October 13, 2016
Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes
Kaori Tane, Chiyomi Egawa, Shintaro Takao, et al.
Lancet (London, England)
|
April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
Page
of 18